Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin


KAYA O., KÖKER G.

Anatolian Journal of Cardiology, cilt.30, sa.10, ss.700-707, 2026 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 10
  • Basım Tarihi: 2026
  • Doi Numarası: 10.14744/anatoljcardiol.2026.6348
  • Dergi Adı: Anatolian Journal of Cardiology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Sayfa Sayıları: ss.700-707
  • Anahtar Kelimeler: diabetes mellitus, Diastolic dysfunction, echocardiography
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: The cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors have attracted increasing interest in patients with type 2 diabetes mellitus. This study aimed to compare the time-dependent effects of empagliflozin and linagliptin on left ventricular diastolic function and global longitudinal strain (GLS). Methods: This prospective longitudinal study included 350 patients with type 2 diabetes mellitus treated with empagliflozin (n=200) or linagliptin (n=150). Transthoracic echocardiography and speckle-tracking strain analysis were performed at baseline, 1 month, and 6 months. Diastolic function was evaluated using septal e' velocity, E/e' ratio, isovolumetric relaxation time (IVRT), and mitral E-wave deceleration time. Longitudinal changes were analyzed using linear mixed-effects models including treatment group, time, and group × time interaction. Results: Diastolic function parameters improved significantly over time in both groups (all P < .001). At follow-up, HbA1c levels decreased in both groups, with comparable glycemic control achieved at 6 months. Significant group × time interactions were observed for septal e' velocity, E/e' ratio, and IVRT (all P < .001). These findings remained consistent after adjustment for baseline differences. At 6 months, empagliflozin was associated with greater improvement in septal e' velocity and IVRT, whereas linagliptin resulted in a more pronounced reduction in the E/e' ratio. Although GLS improved in both groups, its temporal pattern differed significantly between treatments (P < .001). Conclusion: Empagliflozin and linagliptin exert distinct effects on left ventricular diastolic function and myocardial deformation in type 2 diabetes mellitus. Empagliflozin appears to provide earlier improvement in diastolic relaxation and GLS, whereas linagliptin may have a greater effect on filling pressures. These findings should be interpreted cautiously and considered hypothesis-generating; confirmation in randomized controlled trials is required to determine their clinical relevance.